Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
European Journal of Haematology
|
April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Cancer
|
July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Leukemia Research
|
December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model
Pierre Fenaux, John F Seymour, Valeria Santini, et al.
Cancer Medicine
|
December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Rami S Komrokji, Najla H Al Ali, David Sallman, et al.
Leukemia Research
|
November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
Marie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 2009
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng Wei, Xianghong Chen, Kathy Rocha, et al.
The New England Journal of Medicine
|
October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List, Gordon Dewald, John Bennett, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2014
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
Guillermo Garcia-Manero, Hanna J Khoury, Elias Jabbour, et al.
Leukemia & Lymphoma
|
October 25, 2008
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment
Tony Navas, Li Zhou, Myka Estes, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
European Journal of Haematology
|
April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Cancer
|
July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Leukemia Research
|
December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model
Pierre Fenaux, John F Seymour, Valeria Santini, et al.
Cancer Medicine
|
December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Rami S Komrokji, Najla H Al Ali, David Sallman, et al.
Leukemia Research
|
November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
Marie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 2009
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng Wei, Xianghong Chen, Kathy Rocha, et al.
The New England Journal of Medicine
|
October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List, Gordon Dewald, John Bennett, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2014
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
Guillermo Garcia-Manero, Hanna J Khoury, Elias Jabbour, et al.
Leukemia & Lymphoma
|
October 25, 2008
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment
Tony Navas, Li Zhou, Myka Estes, et al.
Page
of 8